Dr Adam Ritchie

Contact information

Email
adam.ritchie@ndm.ox.ac.uk

Telephone
01865 617623

Address
Old Road Campus Research Build (ORCRB), Roosevelt Drive, Oxford OX3 7DQ

Research groups

Adam Ritchie

BSc, PhD, FHEA

Senior Vaccinologist

Douglas Group

Adam is a Senior Vaccinologist at the Jenner Institute. He is currently focused on the rabies, EBV and COVID-19 vaccine projects, alongside work on policy and regulation as part of Vax-Hub Global. Adam's interest is on translation of academic research into real world impact through the efficient development, manufacture, and clinical testing of vaccine candidates.

Adam works includes the design and delivery of early phase clinical trials, regulatory affairs, public policy, and vaccine manufacturing.

Adam is also a Lecturer in Human Science at St Catherine's College.

Key publications

Tetraspanin-based immunocapture for high-depth proteomic profiling of extracellular vesicles from cerebrospinal fluid for biomarker discovery

Dellar ER. et al, (2026), Clinical Proteomics, 23

Advancing the concept of community positive health through participatory research in marginalized communities in Kenya

Peters LER. et al, (2026), Social Science & Medicine, 398, 119147 - 119147

Perceptions of death, dying and the body in Vietnamese culture: A qualitative exploration from a study examining the potentials of minimally invasive tissue sampling in Vietnam

Doan NP. et al, (2026), SSM - Qualitative Research in Health, 9, 100714 - 100714

Ensuring vaccine cold chain integrity: A rapid and low-cost test for identifying heat-exposed sucrose-containing vaccines

Arman BY. et al, (2026), International Journal of Pharmaceutics: X, 11, 100467 - 100467

Rickettsial seropositivity in Lao PDR smallholder livestock farms: Implications for animal and human health.

Tawfik C. et al, (2026), One health (Amsterdam, Netherlands), 22

Deformation-Recovery diffusion model (DRDM): Instance deformation for image manipulation and synthesis

Zheng J-Q. et al, (2026), Medical Image Analysis, 110, 103987 - 103987

Trends in pneumothorax mortality in England (2004–2023): a population-based observational study

Zhong X. et al, (2026), The Lancet Regional Health - Europe, 64, 101632 - 101632

The normalisation of under-resourcing limits the potential for improvement of critical care: evidence from a multi-method study of Kenyan hospitals

McKnight J. et al, (2026), Social Science & Medicine, 396, 118843 - 118843

Toward Integration of Molecular Measures and Artificial Intelligence-Based Assessments With Clinical End Points in Inflammatory Bowel Disease

Reinisch W. et al, (2026), Gastroenterology, 170, 686 - 703

Vibrotactile positional therapy for the treatment of positional obstructive sleep apnoea: a multicentre, randomised controlled trial

Kelly JL. et al, (2026), Thorax, 81, 370 - 379

Acute upper gastrointestinal bleeding in the UK: 2022 audit update

Nigam GB. et al, (2026), Gut, 75, 760 - 771

Voices from the frontline: how global funding cuts are reshaping the viral hepatitis response

Delphin M. et al, (2026), The Lancet Gastroenterology & Hepatology, 11, 269 - 271

Characterisation of bacteria‐induced colitis and its modulation by probiotics in naked mole rats: a new mammalian model for acute inflammatory disease

Hart DW. et al, (2026), The Journal of Pathology, 268, 493 - 511

Prospects and perils of antimicrobial resistance cluster detection using routinely collected data: an illustration from tertiary hospitals in Thailand representing different data contexts

Rangsiwutisak C. et al, (2026), Journal of Hospital Infection, 170, 48 - 59

Age distribution of respiratory syncytial virus disease in children younger than 5 years in low-income and middle-income countries: a systematic review and meta-analysis

Mahmud S. et al, (2026), The Lancet Child & Adolescent Health, 10, 245 - 254

Performance of diagnostic procedures for bubonic plague in endemic settings in Madagascar: a prospective test accuracy sub-study within the IMASOY trial

Raberahona M. et al, (2026), Clinical Microbiology and Infection, 32, 638 - 643

Women with chronic pelvic pain can be stratified using multimodal assessment.

Demetriou L. et al, (2026), Pain, 167, 786 - 802

Cochrane Database of Systematic Reviews

(2026)

Symptom Duration-Dependent Protein Abundance Changes in Symptomatic and Asymptomatic Tendons in Early Stage Unilateral Patellar Tendinopathy.

Steffen D. et al, (2026), J Proteome Res

Skin cancer in transplant recipients: time to revisit immunosuppression trials?

Bottomley MJ., (2026), British Journal of Dermatology, 194, 619 - 620

Chronic Malaria Is Associated With Trauma-related Splenic Rupture Requiring Splenectomy

Shanti PAI. et al, (2026), The Journal of Infectious Diseases, 233, e740 - e744

Assessing the innovation competency and entrepreneurial capacity of health students in Vietnam: a cross-sectional study

Le ANT. et al, (2026), BMC Medical Education

Identification of transporters essential for survival of Leishmania promastigotes in the digestive tract of sand flies

Sádlová J. et al, (2026), PLOS Pathogens, 22, e1014049 - e1014049

Development and Evaluation of Compact Semi-Synthetic Promoters for Enhanced Antigen Expression in Adenoviral-Vectored Vaccines

Hlaváč M. et al, (2026), Vaccines, 14, 260 - 260

Dopamine release from Parkinson's patient-derived neurons is disrupted due to impaired synaptic vesicle loading

Cramb KML. et al, (2026)

Chromosomal instability shapes the tumor microenvironment of esophageal adenocarcinoma via a cGAS–chemokine–myeloid axis

Beernaert B. et al, (2026), Science Advances, 12

Research without borders: advancing equitable global partnerships to accelerate HBV elimination efforts

Batbold E. et al, (2026), Nature Reviews Gastroenterology & Hepatology

Biosafety and biosecurity for Burkholderia pseudomallei and Burkholderia mallei : evidence, gaps, and sustainable practice in endemic, low-resource settings

Blacksell SD. et al, (2026), Clinical Microbiology Reviews

SPICE-GRADE: Simultaneous Processing of Indirect Causal Evidence in Complex Pathways Using GRADE -An Exploratory Case Study.

Eachempati P. et al, (2026), J Clin Epidemiol

Using peptide-exchange systems to interrogate peptide-specific KIR binding to HLA Class I

Murali TM. et al, (2026)

Ubiquitin E3 ligase KLHL6 brings exhausted T-cells back into action

Chen Z. et al, (2026), Immunity & Inflammation, 2

Estimating the changing prevalence of molecular markers of artemisinin partial resistance in Plasmodium falciparum malaria in Sub-Saharan Africa

Harrison LE. et al, (2026)

ESR1 Mutation in Endocrine Treatment-Naïve Endometrial Cancer: Prevalence, Characteristics, and Prognostic Implications, Results from the UTOLA Phase II GINECO Trial

Blanc-Durand F. et al, (2026), Clinical Cancer Research, 32, 963 - 969

Data from ESR1 Mutation in Endocrine Treatment-Naïve Endometrial Cancer: Prevalence, Characteristics, and Prognostic Implications, Results from the UTOLA Phase II GINECO Trial

Blanc-Durand F. et al, (2026)

Supplementary Table S1 from ESR1 Mutation in Endocrine Treatment-Naïve Endometrial Cancer: Prevalence, Characteristics, and Prognostic Implications, Results from the UTOLA Phase II GINECO Trial

Blanc-Durand F. et al, (2026)

Genotype-stratified adjunctive dexamethasone for tuberculous meningitis in HIV-negative adults: a randomized controlled phase 3 trial

Donovan J. et al, (2026), Nature Medicine, 32, 849 - 858

Population pharmacokinetics of lumefantrine in pregnant and non‐pregnant women with uncomplicated Plasmodium falciparum malaria in Western Kenya

Juma E. et al, (2026), British Journal of Clinical Pharmacology, 92, 911 - 921

Burden of chronic respiratory disease in Asia, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023

Jo H. et al, (2026), The Lancet Respiratory Medicine, 14, 233 - 255

The potential of a centrally implemented system for national surveillance of bloodstream infections in England, compared to current local surveillance, 2023–2024

Cregan J. et al, (2026), Journal of Hospital Infection, 169, 5 - 14

Addressing pandemic-wide systematic errors in the SARS-CoV-2 phylogeny

Hunt M. et al, (2026), Nature Methods, 23, 653 - 662

Genotype-stratified adjunctive dexamethasone for tuberculous meningitis in HIV-negative adults: a randomized controlled phase 3 trial

Donovan J. et al, (2026), Nature Medicine, 32, 849 - 858

Risk Factors of Metabolic Dysfunction-associated Steatotic Liver Disease in a Cohort of Patients With Chronic Hepatitis B

Kalafateli M. et al, (2026), Clinical Gastroenterology and Hepatology, 24, 701 - 712.e8

HepB-boost: Implementation of free-of-charge health care worker hepatitis B testing and vaccination at Kilifi County Referral Hospital, Kenya

Downs LO. et al, (2026), International Journal of Infectious Diseases, 164, 108418 - 108418

Intratumoral heterogeneity and immunotherapy resistance: clinical implications

Keenan BP. et al, (2026), Annals of Oncology, 37, 314 - 328

Vaccine effectiveness of a bivalent respiratory syncytial virus (RSV) pre-F vaccine against RSV-associated hospital admission among adults aged 75–79 years in England: a multicentre, test-negative, case–control study

Symes R. et al, (2026), The Lancet Infectious Diseases, 26, 229 - 238

Protocol for stable cell line production to express muscle-type nicotinic receptor

Li A. et al, (2026), STAR Protocols, 7, 104427 - 104427

A National Evaluation of Intercostal Chest Drain Removal Strategies

Veale N. et al, (2026), CHEST, 169, 849 - 858

(Un)intended consequences: a social sciences stocktake of a decade of Global Action Plan-inspired antimicrobial governance

Kirchhelle C. et al, (2026), The Lancet Microbe, 7, 101315 - 101315

Impact of an electronic clinical decision support algorithm (eCDSA) on antibiotic prescribing in primary care in Cambodia: A cluster randomised controlled trial

Wynberg E. et al, (2026), International Journal of Infectious Diseases, 164, 108382 - 108382

Biosafety without borders: bridging the capacity gap in resource-limited laboratory settings

Blacksell SD. and Dhawan S., (2026), The Lancet Microbe, 101394 - 101394

Nasopharyngeal Microbiome Composition and its Clinical Correlates in Children Hospitalized with Severe Pneumonia in East Africa.

Makori TO. et al, (2026), The Journal of infectious diseases

Evaluation of the Bangkok Health Research and Ethics Interest Group: reflecting on the experiences of group members, researchers and facilitators participating in an urban community advisory board in Thailand.

Osterrieder A. et al, (2026), Research involvement and engagement, 12

Patterns of HIV-1 viral load suppression and drug resistance during the dolutegravir transition: a population-based longitudinal study.

Martin MA. et al, (2026), Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Recent publications

Routine childhood rabies pre-exposure prophylaxis can be cost effective in low- and middle-income countries.

Ritchie AJ. et al, (2025), Vaccine, 47

Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial

Madhavan M. et al, (2022), eBioMedicine, 85, 104298 - 104298

Safety and immunogenicity of a simian-adenovirus-vectored rabies vaccine: an open-label, non-randomised, dose-escalation, first-in-human, single-centre, phase 1 clinical trial

Jenkin D. et al, (2022), The Lancet Microbe, 3, e663 - e671

Manufacturing a chimpanzee adenovirus-vectored SARS-CoV-2 vaccine to meet global needs.

Joe CCD. et al, (2022), Biotechnology and bioengineering, 119, 48 - 58

Publisher Correction: Characterisation of factors contributing to the performance of nonwoven fibrous matrices as substrates for adenovirus vectored vaccine stabilisation.

Dulal P. et al, (2021), Scientific reports, 11

Characterisation of factors contributing to the performance of nonwoven fibrous matrices as substrates for adenovirus vectored vaccine stabilisation.

Dulal P. et al, (2021), Scientific reports, 11

Making THE vaccine

Joe CCD. and Ritchie AJ., (2021), Biochemist, 43, 8 - 13

Author Correction: T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial

Ewer KJ. et al, (2021), Nature Medicine, 27, 1116 - 1116

Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses

Barrett JR. et al, (2021), Nature Medicine, 27, 1113 - 1113

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials

Voysey M. et al, (2021), The Lancet, 397, 881 - 891

Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses

Barrett JR. et al, (2021), Nature Medicine, 27, 279 - 288

T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial

Ewer KJ. et al, (2021), Nature Medicine, 27, 270 - 278

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Voysey M. et al, (2021), The Lancet, 397, 99 - 111

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial

Ramasamy MN. et al, (2020), The Lancet, 396, 1979 - 1993

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

Folegatti PM. et al, (2020), The Lancet, 396, 467 - 478

Characterisation of factors contributing to the performance of nonwoven fibrous matrices as substrates for adenovirus vectored vaccine stabilisation

Dulal P. et al, (2020)

Simian adenovirus vector production for early-phase clinical trials: A simple method applicable to multiple serotypes and using entirely disposable product-contact components

Fedosyuk S. et al, (2019), Vaccine, 37, 6951 - 6961